Clostridium novyi-NT

Drug Profile

Clostridium novyi-NT

Alternative Names: BVD-CNV; BVD-CNV/IT; BVD-CNV/IV; Clostridium novyi-NT spores

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMed Valley Discoveries; Johns Hopkins University
  • Developer BioMed Valley Discoveries
  • Class Bacteria
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Feb 2018 BioMed Valley Discoveries and Merck & Co. plan a phase Ib trial of pembrolizumab in combination with for intratumoral Injection of Clostridium Novyi-NT Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in the US (NCT03435952)
  • 29 Nov 2016 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(EORTC-NCI-AACR-2016)
  • 13 Jun 2014 Discontinued - Phase-I for Solid tumours (Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top